منابع مشابه
Aromatase destabilizer: novel action of exemestane, a food and drug administration-approved aromatase inhibitor.
Using Western blot as the major technique, we studied the effects of the three Food and Drug Administration (FDA)-approved aromatase inhibitors (AI) on aromatase protein stability in the aromatase-overexpressing breast cancer cell line MCF-7aro. We have found that exemestane treatment significantly reduces aromatase protein level. Exemestane induces aromatase degradation in a dose-responsive ma...
متن کاملAnastrozole: a new selective nonsteroidal aromatase inhibitor.
Aromatase (estrogen synthetase) is the enzyme complex responsible for the final step in estrogen synthesis--the conversion of androstenedione and testosterone to estrone and estradiol, respectively. Inhibitors of this enzyme have been shown to be clinically effective in the treatment of advanced breast cancer in postmenopausal women, in whom the major source of estrogen production derives from ...
متن کاملAromatase inhibitor-induced arthralgia: a review.
Though aromatase inhibitors (AIs) are an essential part of estrogen receptor-positive (ER+) breast cancer therapy, many patients discontinue the medicine before their adjuvant therapy is completed because of the arthralgia which often accompanies the medicine. Up to half of women on AI therapy experience joint pain, and up to 20% will become non-compliant with the medicine because of the joint ...
متن کاملAppraising adjuvant aromatase inhibitor therapy.
Tamoxifen, once the gold standard adjuvant endocrine therapy for early breast cancer, is being challenged by third-generation aromatase inhibitors (AIs) that have demonstrated improved disease-free survival in a variety of adjuvant settings for early breast cancer. Tamoxifen and AIs have different safety profiles, which should allow physicians to begin to individualize treatment based on a pati...
متن کاملAromatase inhibitor-associated bone loss.
273 A 49-year-old postmenopausal Caucasian woman named M.A. was diagnosed with estrogen receptor (ER)-positive, progesterone receptor (PR)-positive, HER2-negative breast cancer. Anthracycline and taxane-based adjuvant chemotherapy and radiation therapy were followed by adjuvant therapy with an aromatase inhibitor (AI). Before M.A. started adjuvant AI therapy, she was evaluated for any additiona...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Japanese Journal of Pharmacology
سال: 1993
ISSN: 0021-5198
DOI: 10.1016/s0021-5198(19)51591-8